Requests that the FDA amend the approved age indication for the Recombinant Zoster Vaccine (RZV) (Shingrix) to include immunocompetent adults aged 18 and older, or, at a minimum, to lower the indicated age to 40 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-2398

Requests that the FDA amend the approved age indication for the Recombinant Zoster Vaccine (RZV) (Shingrix) to include immunocompetent adults aged 18 and older, or, at a minimum, to lower the indicated age to 40

Documents

Comments

Description

Open

Key Dates

Comment Period OpensMar 9, 2026

Documents

Type	Title	Posted	Comments	Status
Supporting Material	Reference 1	Mar 9, 2026	--

Keywords

CBER

Citizen Petition

Requests that the FDA amend the approved age

indication for the Recombinant Zoster Vaccine

(RZV) (Shingrix) to include immunocompetent

adults aged 18 and older, or, at a minimum, to

lower the indicated age to 40

Open

Data from Regulations.gov